icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
XaNq8nqaXUHrNCkn